1
|
Migueres M, Chapuy‐Regaud S, Miédougé M, Jamme T, Lougarre C, Da Silva I, Pucelle M, Staes L, Porcheron M, Diméglio C, Izopet J. Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection. J Med Virol 2023; 95:e28200. [PMID: 36207814 PMCID: PMC9874650 DOI: 10.1002/jmv.28200] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/12/2022] [Accepted: 10/03/2022] [Indexed: 01/27/2023]
Abstract
The present study aimed to determine whether current commercial immunoassays are adequate for detecting anti-Omicron antibodies. We analyzed the anti-SARS-CoV-2 antibody response of 23 unvaccinated individuals 1-2 months after an Omicron infection. All blood samples were tested with a live virus neutralization assay using a clinical Omicron BA.1 strain and four commercial SARS-CoV-2 immunoassays. We assessed three anti-Spike immunoassays (SARS-CoV-2 IgG II Quant [Abbott S], Wantaï anti-SARS-CoV-2 antibody ELISA [Wantaï], Elecsys Anti-SARS-CoV-2 S assay [Roche]) and one anti-Nucleocapsid immunoassay (Abbott SARS-CoV-2 IgG assay [Abbott N]). Omicron neutralizing antibodies were detected in all samples with the live virus neutralization assay. The detection rate of the Abbott S, Wantai, Roche, and Abbott N immunoassays were 65.2%, 69.6%, 86.9%, and 91.3%, respectively. The sensitivities of Abbott S and Wantai immunoassays were significantly lower than that of the live virus neutralization assay (p = 0.004, p = 0.009; Fisher's exact test). Antibody concentrations obtained with anti-S immunoassays were correlated with Omicron neutralizing antibody concentrations. These data provide clinical evidence of the loss of performance of some commercial immunoassays to detect antibodies elicited by Omicron infections. It highlights the need to optimize these assays by adapting antigens to the circulating SARS-CoV-2 strains.
Collapse
Affiliation(s)
- Marion Migueres
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Sabine Chapuy‐Regaud
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Marcel Miédougé
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Thibaut Jamme
- Laboratoire de Biochimie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | | | - Isabelle Da Silva
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Mélanie Pucelle
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Laetitia Staes
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Marion Porcheron
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance
| | - Chloé Diméglio
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| | - Jacques Izopet
- Laboratoire de Virologie, CHU Toulouse, Hôpital PurpanInstitut Fédératif de BiologieToulouseFrance,Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 ‐ CNRS UMR5051ToulouseFrance,Université Toulouse III Paul‐SabatierToulouseFrance
| |
Collapse
|
2
|
Dimeglio C, Herin F, Da-Silva I, Gernigon C, Porcheron M, Chapuy-Regaud S, Izopet J. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. Microbiol Spectr 2022; 10:e0270621. [PMID: 35867411 PMCID: PMC9430143 DOI: 10.1128/spectrum.02706-21] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 05/16/2022] [Indexed: 12/13/2022] Open
Abstract
The neutralizing antibody response is a key component of adaptive immunity and a primary protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The increased transmissibility of the SARS-CoV-2 Delta variant and its capacity to cause more severe disease could be linked to a significant reduction in neutralizing antibodies generated during a previous infection or vaccination. We analyzed blood samples from 162 unvaccinated health care workers (HCWs) collected 1 to 3 months postinfection and from 263 vaccinated health care workers 1 month after the last injection. We have compared the neutralizing antibody titers obtained using two virus strains, B.1.160 and B.1.617.2 (Delta variant). Binding antibody concentrations were measured by an immunoassay. The median neutralizing antibody titer against the B.1.160 strain was 128 (interquartile range [IQR], 16 to 256) and 32 (IQR, 8 to 128) against the Delta variant. To obtain a neutralizing antibody titer of 32 or 64, a binding antibody concentration of 182 binding antibody units (BAU)/mL (IQR, 81 to 974) was required with the strain B.1.160, while a concentration of 2,595 BAU/mL (IQR, 1,176 to 5,353) was required with the Delta variant. Our data indicate that antibodies neutralize the SARS-CoV-2 Delta variant 4 times less efficiently than they neutralize an earlier strain. Half of the HCWs had decreased protection from 94% to 76.8% or less for the same total antibody concentration. But neutralization might be correlated with other immune responses. The contributions of other responses, such as those of the T cell and B cell systems, to protection require further investigation. IMPORTANCE Recent studies showed that the neutralizing antibody titer is an important contributor to protection against SARS-CoV-2. With the emergence of new variants, the question arises of maintaining the neutralizing capacities of vaccines and/or of a past infection. We had protective data associated with total antibody concentrations and neutralizing antibody titers for a B.1.160 strain. We showed that to maintain the same levels of protection and, therefore, the same levels of neutralizing antibodies, a total antibody concentration 8.5 times greater is required with the Delta strain. (This study has been registered at ClinicalTrials.gov under registration no. NCT04385108.).
Collapse
Affiliation(s)
- Chloé Dimeglio
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France
- INSERM UMR1291 – CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France
| | - Fabrice Herin
- Occupational Diseases Department, Toulouse University Hospital, Toulouse, France
- UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier, Centre for Epidemiology and Research in Population Health Unit (CERPOP), Toulouse, France
| | | | - Caroline Gernigon
- Occupational Diseases Department, Toulouse University Hospital, Toulouse, France
- UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier, Centre for Epidemiology and Research in Population Health Unit (CERPOP), Toulouse, France
| | - Marion Porcheron
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France
| | - Sabine Chapuy-Regaud
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France
- INSERM UMR1291 – CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France
| | - Jacques Izopet
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France
- INSERM UMR1291 – CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France
| |
Collapse
|
3
|
Pierson-Marchandise M, Castelain S, Chevalier C, Brochot E, Schmit JL, Diouf M, Ganry O, Gignon M. Hospital-wide SARS-CoV-2 antibody screening of 4840 staff members in a University Medical Center in France: a cross-sectional study. BMJ Open 2022; 12:e047010. [PMID: 35545377 PMCID: PMC9096052 DOI: 10.1136/bmjopen-2020-047010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES Healthcare workers are more likely to be infected by SARS-CoV-2. In order to assess the infectious risk associated with working in a hospital, we sought to estimate the proportion of healthcare professionals infected with SARS-CoV-2 by screening staff in a University Medical Center in France. SETTING A hospital-wide screening campaign (comprising a serological test and a questionnaire) ran from 18 May to 26 July 2020. PRIMARY AND SECONDARY OUTCOME MEASURES The seroprevalence rate was analysed in a multivariate analysis according to sociodemographic variables (age, sex and profession), exposure to SARS-CoV-2 and symptoms. RESULTS A total of 4840 professionals were included, corresponding to 74.5% of the centre's staff. The seroprevalence rate (95% CI) was 9.7% (7.0% to 12.4%). Contact with a confirmed case of COVID-19 was significantly associated with seropositivity (OR (95% CI: 1.43, (1.15 to 1.78)). The seroprevalence rate was significantly higher among nursing assistants (17.6%) than among other healthcare professionals. The following symptoms were predictive of COVID-19: anosmia (OR (95% CI): 1.55, (1.49 to 1.62)), ageusia (1.21, (1.16 to 1.27)), fever (1.15, (1.12 to 1.18)), myalgia (1.03, (1.01 to 1.06)) and headache (1.03, (1.01 to 1.04)).
Collapse
Affiliation(s)
- Marion Pierson-Marchandise
- Department of Preventions, Risks, Medical Information and Epidemiology, CHU Amiens-Picardie, Amiens, France
| | - Sandrine Castelain
- Department of Virology, CHU Amiens-Picardie, Amiens, France
- AGIR Research Unit, EA 4294, Amiens University, Amiens, France
| | - Cassandra Chevalier
- Department of Preventions, Risks, Medical Information and Epidemiology, CHU Amiens-Picardie, Amiens, France
| | - Etienne Brochot
- Department of Virology, CHU Amiens-Picardie, Amiens, France
- AGIR Research Unit, EA 4294, Amiens University, Amiens, France
| | - Jean-Luc Schmit
- AGIR Research Unit, EA 4294, Amiens University, Amiens, France
- Infectious Disease, CHU Amiens-Picardie, Amiens, France
| | - Momar Diouf
- Department of Statistics, University Hospital Centre Amiens-Picardie, Amiens, France
| | - Olivier Ganry
- Department of Preventions, Risks, Medical Information and Epidemiology, CHU Amiens-Picardie, Amiens, France
| | - Maxime Gignon
- Department of Preventions, Risks, Medical Information and Epidemiology, CHU Amiens-Picardie, Amiens, France
- CRP CPO, Amiens University, Amiens, France
| |
Collapse
|
4
|
Dávila-Conn V, Soto-Nava M, Caro-Vega YN, Paz-Juárez HE, García-Esparza P, Tapia-Trejo D, Pérez-García M, Belaunzarán-Zamudio PF, Reyes-Terán G, Sierra-Madero JG, Galindo-Fraga A, Ávila-Ríos S. Seroepidemiology of SARS-CoV-2 in healthcare personnel working at the largest tertiary COVID-19 referral hospitals in Mexico City. PLoS One 2022; 17:e0264964. [PMID: 35298500 PMCID: PMC8929624 DOI: 10.1371/journal.pone.0264964] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 02/20/2022] [Indexed: 12/23/2022] Open
Abstract
Introduction We performed a longitudinal SARS-CoV-2 seroepidemiological study in healthcare personnel of the two largest tertiary COVID-19 referral hospitals in Mexico City. Methods All healthcare personnel, including staff physicians, physicians in training, nurses, laboratory technicians, researchers, students, housekeeping, maintenance, security, and administrative staff were invited to voluntarily participate, after written informed consent. Participants answered a computer-assisted self-administered interview and donated blood samples for antibody testing every three weeks from October 2020 to June 2021. Results A total of 883 participants (out of 3639 registered employees) contributed with at least one blood sample. The median age was 36 years (interquartile range: 28–46) and 70% were women. The most common occupations were nurse (28%), physician (24%), and administrative staff (22%). Two hundred and ninety participants (32.8%) had a positive-test result in any of the visits, yielding an overall adjusted prevalence of 33.5% for the whole study-period. Two hundred and thirty-five positive tests were identified at the baseline visit (prevalent cases), the remaining 55 positive tests were incident cases. Prevalent cases showed associations with both occupational (institution 2 vs. 1: adjusted odds ratio [aOR] = 2.24, 95% confidence interval [CI]: 1.54–3.25; laboratory technician vs. physician: aOR = 4.38, 95% CI: 1.75–10.93) and community (municipality of residence Xochimilco vs. Tlalpan: aOR = 2.03, 95% CI: 1.09–3.79) risk-factors. The incidence rate was 3.0 cases per 100 person-months. Incident cases were associated with community-acquired risk, due to contact with suspect/confirmed COVID-19 cases (HR = 2.45, 95% CI: 1.21–5.00). Conclusions We observed that between October 2020 and June 2021, healthcare workers of the two largest tertiary COVID-19 referral centers in Mexico City had similar level of exposure to SARS-CoV-2 than the general population. Most variables associated with exposure in this setting pointed toward community rather than occupational risk. Our observations are consistent with successful occupational medicine programs for SARS-CoV-2 infection control in the participating institutions but suggest the need to strengthen mitigation strategies in the community.
Collapse
Affiliation(s)
- Vanessa Dávila-Conn
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | - Maribel Soto-Nava
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | - Yanink N. Caro-Vega
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Héctor E. Paz-Juárez
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | - Pedro García-Esparza
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | - Daniela Tapia-Trejo
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | - Marissa Pérez-García
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
| | | | - Gustavo Reyes-Terán
- Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud de México, Mexico City, Mexico
| | - Juan G. Sierra-Madero
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Arturo Galindo-Fraga
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Santiago Ávila-Ríos
- Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
- * E-mail:
| |
Collapse
|
5
|
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and caused a dramatic pandemic. Serological assays are used to check for immunization and assess herd immunity. We evaluated commercially available assays designed to quantify antibodies directed to the SARS-CoV-2 Spike (S) antigen, either total (Wantaï SARS-CoV-2 Ab ELISA) or IgG (SARS-CoV-2 IgG II Quant on Alinity, Abbott, and Liaison SARS-CoV-2 TrimericS IgG, Diasorin). The specificities of the Wantaï, Alinity, and Liaison assays were evaluated using 100 prepandemic sera and were 98, 99, and 97%, respectively. The sensitivities of all three were around 100% when tested on 35 samples taken 15 to 35 days postinfection. They were less sensitive for 150 sera from late infections (>180 days). Using the first WHO international standard (NIBSC), we showed that the Wantai results were concordant with the NIBSC values, while Liaison and Alinity showed a proportional bias of 1.3 and 7, respectively. The results of the 3 immunoassays were significantly globally pairwise correlated and for late infection sera (P < 0.001). They were correlated for recent infection sera measured with Alinity and Liaison (P < 0.001). However, the Wantai results of recent infections were not correlated with those from Alinity or Liaison. All the immunoassay results were significantly correlated with the neutralizing antibody titers obtained using a live virus neutralization assay with the B1.160 SARS-CoV-2 strain. These assays will be useful once the protective anti-SARS-CoV-2 antibody titer has been determined. IMPORTANCE Standardization and correlation with virus neutralization assays are critical points to compare the performance of serological assays designed to quantify anti-SARS-CoV-2 antibodies in order to identify their optimal use. We have evaluated three serological immunoassays based on the virus spike antigen that detect anti-SARS-CoV-2 antibodies: a microplate assay and two chemiluminescent assays performed with Alinity (Abbott) and Liaison (Diasorin) analysers. We used an in-house live virus neutralization assay and the first WHO international standard to assess the comparison. This study could be useful to determine guidelines on the use of serological results to manage vaccination and treatment with convalescent plasma or monoclonal antibodies.
Collapse
|
6
|
Antibody titers and protection against a SARS-CoV-2 infection. J Infect 2021; 84:248-288. [PMID: 34560135 PMCID: PMC8452591 DOI: 10.1016/j.jinf.2021.09.013] [Citation(s) in RCA: 74] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 09/16/2021] [Indexed: 12/14/2022]
|
7
|
The front-line during the coronavirus disease 2019 pandemic: healthcare personnel. Curr Opin Infect Dis 2021; 34:372-383. [PMID: 34227581 DOI: 10.1097/qco.0000000000000734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE OF REVIEW An estimated four to 11% of reported coronavirus disease 2019 (COVID-19) cases occurs in healthcare personnel (HCP). HCP are at high risk of acquiring and transmitting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) given their close contact with individuals with recognized and unrecognized COVID-19. We summarize the literature to date describing the epidemiology, identifying risk factors associated with COVID-19, and analyzing clinical characteristics and outcomes of SARS-CoV-2 infection in HCP. RECENT FINDINGS The prevalence of SARS-CoV-2 antibodies among HCP ranges from 0.7 to 45%. Although there is heterogeneity in the seroprevalence rate reported in the literature, HCP may be at increased risk of SARS-CoV-2 infection from exposure to patients with COVID-19. The literature supports that this can be minimized with adequate personal protective equipment (PPE) supply, proper hand hygiene, appropriate PPE use, and other infection prevention measures. In addition, infections in HCP are commonly acquired in the community as well as in nonclinical care settings including break rooms or work rooms. SUMMARY While much focus has been on minimizing patient-to-HCP transmission of SARS-CoV-2, additional efforts are needed to prevent exposures in nonclinical care settings and in the community.
Collapse
|
8
|
Vitrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, Valran A, Bosch A, Noret M, Delory T. Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines (Basel) 2021; 9:824. [PMID: 34451949 PMCID: PMC8402428 DOI: 10.3390/vaccines9080824] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 07/05/2021] [Accepted: 07/22/2021] [Indexed: 01/09/2023] Open
Abstract
We aimed to report SARS-CoV-2 seroprevalence after the first wave of the pandemic among healthcare workers, and to explore factors associated with an increased infection rate. We conducted a multicentric cross-sectional survey from 27 June to 31 September 2020. For this survey, we enrolled 3454 voluntary healthcare workers across four participating hospitals, of which 83.4% were female, with a median age of 40.6 years old (31.8-50.3). We serologically screened the employees for SARS-CoV-2, estimated the prevalence of infection, and conducted binomial logistic regression with random effect on participating hospitals to investigate associations. We estimated the prevalence of SARS-CoV-2 infection at 5.0% (95 CI, 4.3%-5.8%). We found the lowest prevalence in health professional management support (4.3%) staff. Infections were more frequent in young professionals below 30 years old (aOR = 1.59, (95 CI, 1.06-2.37)), including paramedical students and residents (aOR = 3.38, (95 CI, 1.62-7.05)). In this group, SARS-CoV-2 prevalence was up 16.9%. The location of work and patient-facing role were not associated with increased infections. Employees reporting contacts with COVID-19 patients without adequate protective equipment had a higher rate of infection (aOR = 1.66, (95 CI, 1.12-2.44)). Aerosol-generating tasks were associated with a ~1.7-fold rate of infection, regardless of the uptake of FFP2. Those exposed to clusters of infected colleagues (aOR = 1.77, (95 CI, 1.24-2.53)) or intra-familial COVID-19 relatives (aOR = 2.09, (95 CI, 1.15-3.80)) also had a higher likelihood of infection. This report highlights that a sustained availability of personal protective equipment limits the SARS-CoV-2 infection rate to what is measured in the general population. It also pinpoints the need for dedicated hygiene training among young professionals, justifies the systematic eviction of infected personnel, and stresses the need for interventions to increase vaccination coverage among any healthcare workers.
Collapse
Affiliation(s)
- Virginie Vitrat
- Infectious Diseases Department, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France;
| | - Alexis Maillard
- Clinical Research Unit, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France; (A.M.); (M.N.); (T.D.)
| | - Alain Raybaud
- Occupational Medicine Department, Alpes Leman Hospital, 74130 Contamine sur Arves, France;
| | - Chloé Wackenheim
- Infectious Diseases Department, Alpes Leman Hospital, 74130 Contamine sur Arves, France;
| | - Bruno Chanzy
- Virology Laboratory, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France;
| | - Sophie Nguyen
- Hygiene Unit, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France;
| | - Amélie Valran
- Infectious Diseases Department, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France;
| | - Alexie Bosch
- Infectious Diseases Department, Metropole Savoie Hospital, 73000 Chambery, France;
| | - Marion Noret
- Clinical Research Unit, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France; (A.M.); (M.N.); (T.D.)
| | - Tristan Delory
- Clinical Research Unit, Annecy Genevois Hospital, 74370 Epagny Metz-Tessy, France; (A.M.); (M.N.); (T.D.)
| |
Collapse
|
9
|
The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. Sci Rep 2021; 11:12597. [PMID: 34131234 PMCID: PMC8206100 DOI: 10.1038/s41598-021-92131-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 06/03/2021] [Indexed: 01/12/2023] Open
Abstract
The SARS-CoV-2 virus has spread world-wide since December 2019, killing more than 2.9 million of people. We have adapted a statistical model from the SIR epidemiological models to predict the spread of SARS-CoV-2 in France. Our model is based on several parameters and assumed a 4.2% seroprevalence in Occitania after the first lockdown. The recent use of serological tests to measure the effective seroprevalence of SARS-CoV-2 in the population of Occitania has led to a seroprevalence around 2.4%. This implies to review the parameters of our model to conclude at a lower than expected virus transmission rate, which may be due to infectivity varying with the patient’s symptoms or to a constraint due to an uneven population geographical distribution.
Collapse
|
10
|
Abbas S, Raza A, Iftikhar A, Khan A, Khan S, Yusuf MA. Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan. Asia Pac J Public Health 2021; 33:632-634. [PMID: 33880961 DOI: 10.1177/10105395211011010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Salma Abbas
- Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
| | - Aun Raza
- Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
| | - Ayesha Iftikhar
- Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
| | - Aamir Khan
- Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
| | - Shahzaib Khan
- Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
| | | |
Collapse
|
11
|
Effectiveness of Preventive Measures in Keeping Low Prevalence of SARS-CoV-2 Infection in Health Care Workers in a Referral Children's Hospital in Southern Italy. Pediatr Rep 2021; 13:118-124. [PMID: 33806472 PMCID: PMC8006005 DOI: 10.3390/pediatric13010017] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 02/08/2021] [Accepted: 03/01/2021] [Indexed: 12/24/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic now represents a major threat to public health. Health care workers (HCW) are exposed to biological risk. Little is currently known about the risk of HCW operating in pediatric wards for SARS-CoV-2 infection. The aim is to assess the prevalence of SARS-CoV-2 infection in HCW in a third-level children's hospital in Southern Italy. An observational cohort study of all asymptomatic HCW (physician, technicians, nurses, and logistic and support operators) was conducted. HCW were screened, on a voluntary basis, for SARS-CoV-2 by RT-PCR on nasopharyngeal swab performed during the first wave of COVID-19. The study was then repeated, with the same modalities, at a 7-month interval, during the "second wave" of the COVID-19 pandemic. At the initial screening between 7 and 24 April 2020, 525 HCW were tested. None of them tested positive. At the repeated screening, conducted between 9 and 20 November 2020, 627 HCW were tested, including 61 additional ones resulting from COVID-emergency recruitment. At this second screening, eight subjects (1.3%) tested positive, thus being diagnosed as asymptomatic carriers of SARS-CoV-2. They were one physician, five nurses, and two HCW from the logistic/support services. They were employed in eight different wards/services. In all cases, the epidemiological investigation showed convincing evidence that the infection was acquired through social contacts. The study revealed a very low circulation of SARS-CoV-2 infection in HCW tested with RT-PCR. All the infections documented in the second wave of epidemic of SARS-CoV-2 were acquired outside of the workplace, confirming that in a pediatric hospital setting, HCW education, correct use of personal protective equipment, and separation of the COVID-patient pathway and staff flow may minimize the risk derived from occupational exposure.
Collapse
|
12
|
Chou R, Dana T, Selph S, Totten AM, Buckley DI, Fu R. Update Alert 6: Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers. Ann Intern Med 2021; 174:W18-W19. [PMID: 33226856 PMCID: PMC7711654 DOI: 10.7326/l20-1323] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Roger Chou
- Pacific Northwest Evidence-based Practice Center and Oregon Health & Science University, Portland, Oregon
| | - Tracy Dana
- Pacific Northwest Evidence-based Practice Center and Oregon Health & Science University, Portland, Oregon
| | - Shelley Selph
- Pacific Northwest Evidence-based Practice Center and Oregon Health & Science University, Portland, Oregon
| | - Annette M Totten
- Pacific Northwest Evidence-based Practice Center and Oregon Health & Science University, Portland, Oregon
| | - David I Buckley
- Pacific Northwest Evidence-based Practice Center and School of Public Health, Oregon Health & Science University-Portland State University, Portland, Oregon
| | - Rongwei Fu
- Pacific Northwest Evidence-based Practice Center and School of Public Health, Oregon Health & Science University-Portland State University, Portland, Oregon
| |
Collapse
|